Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AMLX vs NTLA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AMLX Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 8–1 Matrix Metrics)

AMLX Overall Winner 6-Pillar Tally: AMLX 4 – 2 NTLA Matrix Metrics: AMLX 8 – 1 NTLA

As of Nov 16, 2026, Amylyx Pharmaceuticals, Inc. (AMLX) is the stronger overall head-to-head candidate over Intellia Therapeutics, Inc (NTLA) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). AMLX carries a Unified Composite Score of 59.8/100 (HOLD) at $28.23 (2.8x Forward P/E, 0.0% operating margin), whereas NTLA carries 50.7/100 (HOLD) at $10.00 (N/M Forward P/E, -826.0% operating margin).

  • Growth vs. Quality Trade-Off: AMLX earns the overall head-to-head edge with a stronger Unified Composite Score (59.8/100 HOLD vs. NTLA 50.7/100 HOLD) and 1.16β · 59% Vol risk profile, whereas NTLA leads top-line expansion (-48.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: AMLX is currently in a Breakdown options structure phase (RSI 46.7); meanwhile NTLA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AMLX vs NTLA
AMLX NASDAQ Head-to-Head Winner
Amylyx Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$28.23
-6.78% 1D
Market Cap $3.8B
TTM Revenue N/A
Forward P/E 2.8x
Beta / 30D Vol 1.16β · 59% Vol
Unified Composite Score
59.8 / 100 HOLD
Tech 49.0 Fund 55.0 Flow 64.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.7 · SMA20: $28.98 · SMA50: $29.53
NTLA NASDAQ
Intellia Therapeutics, Inc
In Vitro & In Vivo Diagnostic Substances
$10.00
+3.09% 1D
Market Cap $1.5B
TTM Revenue $53M
Forward P/E N/M
Beta / 30D Vol 2.30β · 87% Vol
Unified Composite Score
50.7 / 100 HOLD
Tech 47.0 Fund 55.0 Flow 59.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.2%), weak momentum, RSI 39
RSI-14: 39.0 · SMA20: $11.58 · SMA50: $11.86

6-Pillar Scorecard Institutional Category Breakdown (AMLX 4 – 2 NTLA)

Columns: Metric · AMLX · NTLA
1. Valuation Multiples AMLX
Forward P/E 2.8x N/M
Trailing P/E 2.8x N/M
PEG Ratio N/M N/M
EV / Revenue N/M 29.1x
2. Growth & Scale NTLA
Revenue Growth (YoY) -99.6% -48.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $53M
Market Cap $3.8B $1.5B
3. Profitability & Quality AMLX
Gross Margin N/A N/A
Operating Margin 0.0% -826.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -30.1% -62.6%
4. Balance Sheet & Cash Flow AMLX
Cash Generation (TTM) -$130M -$358M
Cash Flow Margin N/A N/A
Net Cash / Leverage $235M Net Cash $74M Net Debt (0.38x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AMLX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 61.4% (10th %ile) 101.3% (78th %ile)
Put/Call OI Skew N/A 0.42x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat NTLA
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AMLX (8) vs NTLA (1)
Institutional Metric AMLX NTLA Criterion Row Edge
Market Capitalization
Scale
$3.8B $1.5B Larger Scale AMLX
Trailing P/E Ratio
Valuation
2.8x N/M Lower Multiple AMLX
Forward P/E Ratio
Valuation
2.8x N/M Lower Multiple AMLX
Revenue Growth (YoY)
Growth
-99.6% -48.0% Higher Growth NTLA
Operating Margin (TTM)
Profitability
0.0% -826.0% Higher Margin AMLX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-30.1% -62.6% Higher ROE AMLX
52-Week Range Position
Momentum
57% ($11–$41) 20% ($8–$18) Stronger Trend AMLX
Beta / 30D Volatility
Risk Regime
1.16β · 59% Vol 2.30β · 87% Vol Lower Realized Risk AMLX
Unified Institutional Score
Composite Signal
59.8 / 100 (HOLD) 50.7 / 100 (HOLD) Higher Composite AMLX
Trailing 12M Revenue (USD)
Operating Scale
N/A $53M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 29.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$130M ($235M Net Cash) -$358M ($74M Net Debt (0.38x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AMLX +19.62 pp
AMLX: +7.19% · NTLA: -12.43%
3M Horizon NTLA +5.79 pp
AMLX: -19.58% · NTLA: -13.79%
6M Horizon AMLX +140.76 pp
AMLX: +119.56% · NTLA: -21.2%
1Y Horizon AMLX +111.99 pp
AMLX: +127.33% · NTLA: +15.34%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AMLX Revenue NTLA Revenue AMLX Op. Margin NTLA Op. Margin Margin Leader
FY2018 N/A $30M N/A -298.6% NTLA
FY2019 N/A $40M N/A -246.8% NTLA
FY2020 N/A $60M N/A -235.5% NTLA
FY2021 $0M $30M -29013.3% -810.4% NTLA
FY2022 $20M $50M -905.7% -879.0% NTLA
FY2023 $380M $40M 10.2% -1420.5% AMLX
FY2024 $90M $60M -360.2% -923.1% AMLX
FY2025 N/A $70M N/A -651.7% NTLA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AMLX BREAKDOWN
61d in phase · OBV ACCUMULATION
Current IV 61.4%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact AMLX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NTLA BREAKDOWN
94d in phase · OBV DISTRIBUTION
Current IV 101.3%
IV Percentile 78th %ile
Put/Call OI Skew 0.42x (Call-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NTLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AMLX Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $3.8B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NTLA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.5B market capitalization and -826.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · CRISPR / Gene Editing

Investor FAQ AMLX vs NTLA Key Questions & Quantitative Answers

As of Nov 16, 2026, Amylyx Pharmaceuticals, Inc. (AMLX) is the stronger overall head-to-head candidate over Intellia Therapeutics, Inc (NTLA) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). AMLX carries a Unified Composite Score of 59.8/100 (HOLD) at $28.23 (2.8x Forward P/E, 0.0% operating margin), whereas NTLA carries 50.7/100 (HOLD) at $10.00 (N/M Forward P/E, -826.0% operating margin). Growth vs. Quality Trade-Off: AMLX earns the overall head-to-head edge with a stronger Unified Composite Score (59.8/100 HOLD vs. NTLA 50.7/100 HOLD) and 1.16β · 59% Vol risk profile, whereas NTLA leads top-line expansion (-48.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: AMLX is currently in a Breakdown options structure phase (RSI 46.7); meanwhile NTLA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NTLA leads the Growth & Scale pillar: AMLX posts -99.6% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with NTLA at -48.0% YoY revenue growth and +0.0% YoY earnings growth on $53M TTM revenue (N/A gross margin, -826.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), AMLX cumulative revenue shifted +350.0% while NTLA shifted +133.3%. In operating R&D and SG&A reinvestment, AMLX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NTLA.

AMLX screens cheaper on headline valuation multiples. AMLX trades at 2.8x Forward P/E, 2.8x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas NTLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 29.1x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AMLX (-30.1% ROE) versus NTLA (-62.6% ROE) capital efficiency.

In options market volatility and institutional positioning, AMLX carries 61.4% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.16β · 59% Vol realized risk). By comparison, NTLA carries 101.3% implied volatility (78th %ile, Elevated (60th–80th %ile)), a 0.42x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.30β · 87% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.